NCT00092898An Investigational Drug Study to Lower Non-Cholesterol Sterol Levels Associated With Sitosterolemia (0653-062)(COMPLETED)Lipid Metabolism, Inborn Errors
NCT00092586Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040)Hypercholesterolemia
Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040)
Inclusion Criteria:
* Men or women \>18 and \<80 years of age
* Patients receiving statin therapy for a minimum period of 6 weeks prior to visit 1
* Female patients receiving hormone therapy (including hormone replacement therapy, any estrogen antagonist/agonist, or oral contraceptives) if maintain...
Frequently asked questions about MK0653, ezetimibe
What is MK-0653 used for?
MK-0653, also known as ezetimibe, is used for hypercholesterolemia, including conditions like mixed hyperlipidemia and elevated cholesterol with coronary heart disease. It is being developed for lipid metabolism disorders and is in Phase 3 clinical trials.
What does MK-0653 target?
MK-0653 targets cholesterol absorption in the intestine. It is a small molecule that inhibits the absorption of cholesterol from the diet, thereby lowering blood cholesterol levels. This mechanism is relevant for treating hypercholesterolemia and related lipid disorders.
Who makes MK-0653?
MK-0653 is being developed by Organon & Co., a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol OGN. The company is conducting Phase 3 clinical trials for this drug.
What phase is MK-0653 in?
MK-0653 is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. All nine clinical trials for MK-0653 have been completed, with no active trials currently ongoing.
What clinical trials is MK-0653 in?
MK-0653 has been studied in several Phase 3 clinical trials, including NCT00092560, NCT00092573, NCT00092599, and NCT00092612. These trials enrolled patients with hypercholesterolemia, hypertriglyceridemia, and coronary heart disease, with a total enrollment of over 6,000 participants.
Is MK-0653 the same as ezetimibe?
Yes, MK-0653 is also known as ezetimibe. This alternative name is used in clinical trial titles and medical literature. Ezetimibe is the generic name for this cholesterol-lowering medication.